The Institute for Clinical and Economic Review plans to evaluate the comparative clinical effectiveness and value of abuse-deterrent opioids in the coming months, with a focus on both approved drugs and pipeline products that may be approved in the next few months.
A draft report on the evaluation is schedule to be released Jan. 25, 2017, followed by an expert panel review...






